rood blauwe elepsis logo Belegger.nl

BioPharma Terug naar discussie overzicht

GNBT !!!

2.656 Posts
Pagina: «« 1 ... 88 89 90 91 92 ... 133 »» | Laatste | Omlaag ↓
  1. Nel 4 maart 2006 23:32
    reactie op alex:

    Milestones

    Generex Biotechnology Corporation has achieved numerous milestones over the last 7 years. The timeline below highlights some of our key achievements.

    2005
    Officially launches Oral-lyn™ in Ecuador
    Mice with Human Antigen Presenting Molecules Demonstrate Strong Responses to Novel Melanoma Peptide Vaccine…Destined for Clinical Trials.
    Pandemic Influenza Vaccine Development Accelerated at Generex Biotechnology with Hire of Accomplished Senior Scientist, Dr. John Zinckgraf, Ph.D.
    Acquisition of Custom-Made, Fully-Automated Equipment for Commercial Generex Oral-lyn™ Production.
    Begins Research Collaboration on Novel Allergy Therapy With Stallergenes, S.A.
    Enters Into Middle Eastern Licensing Arrangement with MedGen Corp. for Generex Oral-lyn™.
    Generex Oral-lyn™ approved for commericialization is Ecuador, a world's first regulatory approval of a non-injectible insulin.
    Express Initiates Clinical Trials in Patients with Her-2/neu Positive Breast Cancer.
    Reports that Generex Oral-lyn™ Matches Fast-Acting Insulin in Phase IIb Study.
    Established collaborations with Emory University and the Imperial College of London to develop a novel smallpox vaccine.
    Reports Preliminary Results of a Phase 2b Clinical Study of Generex Oral-lyn™.

    is dus al in de handel via Pharmabrand

    www.pharmabrand.com.ec/

    succes
  2. Nel 4 maart 2006 23:33
    Officially launches Oral-lyn™ in Ecuador
    marktwaarde boven de 300mln dollar
  3. [verwijderd] 5 maart 2006 09:30
    According to the IDF Diabetes Atlas 2nd edition, in 2003 the five countries with the largest numbers of persons with diabetes were India (35.5 million), China (23.8 million), the United States (16 million), Russia (9.7 million) and Japan (6.7 million).

    Ik snap niet dat ze nog zoveel moeite doen om de U.S in te komen.

    Skip the U.S and go elsewhere.
    Als die kuttekoppen daar niet in het gareel willen vallen ze maar dood.

    Ga naar China en India daar ligt genoeg potentie.

    GRoet,Ronald.
  4. [verwijderd] 5 maart 2006 09:38
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 28, 2006

    GENEREX BIOTECHNOLOGY CORPORATION
    (Exact Name of Registrant as Specified in Its Charter)

    Delaware 000-25169 98-0178636
    (State or Other (Commission (IRS Employer
    Jurisdiction of File Number) Identification
    Incorporation) Number)



    33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J 2G2
    (Address of Principal Executive Offices) (Zip Code)


    Registrant’s telephone number, including area code: (416) 364-2551

    N/A
    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

    o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    --------------------------------------------------------------------------------

    Item 1.01 Entry into a Material Definitive Agreement.
    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
    Item 3.02 Unregistered Sales of Equity Securities.
    Item 3.03 Material Modification to Rights of Security Holders.

    As previously reported on the Current Report on Form 8-K of Generex Biotechnology Corporation (the “Company”) filed with the Securities Exchange Commission on January 20, 2006, the Company issued additional investment rights (the “AIRs”) to each of Iroquois Capital LP, Cranshire Capital, L.P., Smithfield Fiduciary LLC and Omicron Master Trust (collectively, the “Investors”) on January 20, 2006 pursuant to which the Company granted to each of the Investors the right to purchase detachable units consisting of (i) $1,000,000 principal amount debentures convertible into common stock at a conversion price of $1.25 (the “AIR Debentures”), and (ii) warrants entitling the holder thereof to purchase a number of shares of the Company’s common stock equal to 100% of the shares of common stock issuable upon the conversion in full of the AIR Debentures at a $1.25 conversion price (800,000 shares) at an exercise price of $1.25 per share. The AIRs were each originally exercisable on 181 st day after January 20, 2006. On February 28, 2006, each of the Investors agreed to immediately exercise 100% of the AIRs (for aggregate gross proceeds to the Company of $4,000,000) in exchange for the acceleration of the exercise periods.

    The Company undertook the offer and sale of the AIRs, as well as the shares of common stock into which such AIRs are exercisable, in reliance upon Rule 506 of Regulation D and Section 18(b)(4)(D) of the Securities Act o f 1933, as amended (the “Securities Act”). Each of the Investors has previously represented and warranted to the Company that it is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act. The sale of such securities did not involve the use of underwriters, and no commissions were paid in connection therewith.


    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

    4.1 Agreement to Amend Additional Investment Right between the Company and Cranshire Capital, L.P. dated February 28, 2006.

    4.2 Agreement to Amend Additional Investment Right between the Company and Omicron Master Trust dated February 28, 2006.

    4.3 Agreement to Amend Additional Investment Right between the Company and Iroquois Capital LP dated February 28, 2006.

    4.4 Agreement to Amend Additional Investment Right between the Company and Smithfield Fiduciary LLC dated February 28, 2006.

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    GENEREX BIOTECHNOLOGY CORPORATION




    Dated: February 28, 2006 By: /s/ Rose Perri

    --------------------------------------------------------------------------------
    Chief Operating Officer and
    Chief Financial Officer
    (principal financial officer)



    --------------------------------------------------------------------------------


    EXHIBIT INDEX

    4.1 Agreement to Amend Additional Investment Right between the Company and Cranshire Capital, L.P. dated February 28, 2006.

    4.2 Agreement to Amend Additional Investment Right between the Company and Omicron Master Trust dated February 28, 2006.

    4.3 Agreement to Amend Additional Investment Right between the Company and Iroquois Capital LP dated February 28, 2006.

    4.4 Agreement to Amend Additional Investment Right between the Company and Smithfield Fiduciary LLC dated February 28, 2006.



    --------------------------------------------------------------------------------



    Exhibit 4.1

    February 28, 2006

    Cranshire Capital, L.P.
    666 Dundee Road
    Suite 1901
    Northbrook, Illinois
    USA 60062
    Attention: Mitchell P. Kopin

    Dear Sirs:

    Re: Generex Biotechnology Corporation
    - Amendment to Jan 20 06 Additional Investment Right


    We make reference to the additional investment right issued by Generex Biotechnology Corporation (the “ Company ”) to Cranshire Capital, L.P. (“ Cranshire ”) on January 20, 2006 pursuant to which the Company, inter alia , granted to Cranshire the right to purchase a $1,000,000 principal amount debenture convertible at $1.25 per share (the “ AIR ”).

    The Initial Exercise Date (as that term is defined in the AIR) of the AIR is expressed therein as the 181 st day after the date thereof. The Company hereby confirms that, in consideration of the exercise of the AIR by Cranshire and the delivery to the Company of a Notice of Exercise in respect thereof on or before the close of business on February 28, 2006, the Company has agreed to abridge the Initial Exercise Date and to honor the aforementioned Notice of Exercise.

    Yours truly,

    Generex Biotechnology Corporation

    /s/ Mark A. Fletcher

    Mark A. Fletcher
    Executive Vice-President, General Counsel
    maf:hs




    --------------------------------------------------------------------------------




    Exhibit 4.2



    February 28, 2006

    Omicron Master Trust
    650 Fifth Avenue
    24 th Floor
    New York, New York
    USA 10019
    Attention: Brian Daly

    Dear Sirs:

    Re: Generex Biotechnology Corporation
    - Amendment to Jan 20 06 Additional Investment Right


    We make reference to the additional investment right issued by Generex Biotechnology Corporation (the “ Company ”) to Omicron Master Trust (“ Omicron ”) on January 20, 2
  5. [verwijderd] 5 maart 2006 09:41
    LAS VEGAS--(BUSINESS WIRE)--Dec. 23, 2005--AXM Pharma, Inc. (Amex: AXJ - News), a manufacturer of proprietary and generic pharmaceutical and nutraceutical products for the Chinese and other Asian markets, announced today that its wholly-owned subsidiary AXM Pharma, (Shenyang) Inc., has received approval from the Chinese Food and Drug Administration to sell Glucostrim(TM) (Qiyao) Anti-diabetes Capsules in China, its new treatment for diabetes. The Company received a New Drug Certificate, allowing it to produce and sell the product commencing in March.

    According to The Asia Times, there are now 90 million people with diabetes in Asia. Asia is home to four of the world's five largest diabetic populations -- India, 33 million people with diabetes; China, 23 million; Pakistan, 9 million; and Japan, 7 million. Globally, the World Health Organization estimates the global diabetes population will grow to more than 200 million in 2010 and 330 million in 2025. The burden in Asia will increase -- in less than a decade 60% of all diabetes cases globally are expected to be in Asia
  6. [verwijderd] 5 maart 2006 11:14
    v/d
    quote:

    ronald76 schreef:

    According to the IDF Diabetes Atlas 2nd edition, in 2003 the five countries with the largest numbers of persons with diabetes were India (35.5 million), China (23.8 million), the United States (16 million), Russia (9.7 million) and Japan (6.7 million).

    Ik snap niet dat ze nog zoveel moeite doen om de U.S in te komen.

    Skip the U.S and go elsewhere.
    Als die kuttekoppen daar niet in het gareel willen vallen ze maar dood.

    Ga naar China en India daar ligt genoeg potentie.

    GRoet,Ronald.

    Waar denk je dat ze meeste winst per patient kunnen maken?

    Juist in de U.S. en eenmaal FDA-goedkeuring,dan volgt de rest vanzelf.
    Zoals normaal in 99 v/d 100 beleggingen moet je gewoon geduld hebben.

    Mcrel
  7. [verwijderd] 5 maart 2006 13:16
    quote:

    mcrel schreef:

    v/d [quote=ronald76]
    According to the IDF Diabetes Atlas 2nd edition, in 2003 the five countries with the largest numbers of persons with diabetes were India (35.5 million), China (23.8 million), the United States (16 million), Russia (9.7 million) and Japan (6.7 million).

    Ik snap niet dat ze nog zoveel moeite doen om de U.S in te komen.

    Skip the U.S and go elsewhere.
    Als die kuttekoppen daar niet in het gareel willen vallen ze maar dood.

    Ga naar China en India daar ligt genoeg potentie.

    GRoet,Ronald.

    [/quote]
    Waar denk je dat ze meeste winst per patient kunnen maken?

    Juist in de U.S. en eenmaal FDA-goedkeuring,dan volgt de rest vanzelf.
    Zoals normaal in 99 v/d 100 beleggingen moet je gewoon geduld hebben.

    Mcrel
    WInst per patient is belangrijk,in een vroeg stadium als dit is ok het aantal patienten belangrijk.
    Des te meer mensen het medicijn gebruiken en er baat bij hebben,des te makkelijker het word toestemming te krijgen van bv. die yanken.

    Groet, Ronald.
  8. Henk Snaph 5 maart 2006 14:12
    quote:

    ronald76 schreef:

    [quote=mcrel]
    v/d [quote=ronald76]
    According to the IDF Diabetes Atlas 2nd edition, in 2003 the five countries with the largest numbers of persons with diabetes were India (35.5 million), China (23.8 million), the United States (16 million), Russia (9.7 million) and Japan (6.7 million).

    Ik snap niet dat ze nog zoveel moeite doen om de U.S in te komen.

    Skip the U.S and go elsewhere.
    Als die kuttekoppen daar niet in het gareel willen vallen ze maar dood.

    Ga naar China en India daar ligt genoeg potentie.

    GRoet,Ronald.

    [/quote]
    Waar denk je dat ze meeste winst per patient kunnen maken?

    Juist in de U.S. en eenmaal FDA-goedkeuring,dan volgt de rest vanzelf.
    Zoals normaal in 99 v/d 100 beleggingen moet je gewoon geduld hebben.

    Mcrel
    [/quote]

    WInst per patient is belangrijk,in een vroeg stadium als dit is ok het aantal patienten belangrijk.
    Des te meer mensen het medicijn gebruiken en er baat bij hebben,des te makkelijker het word toestemming te krijgen van bv. die yanken.

    Groet, Ronald.
    Mijn visie is dat na de ontmoeting met de canadese overheid het projekt sneller zal verlopen dan tot nu toe.
    Deze uitnodiging is niet voor niets aan Generex gedaan. Wie zegt dat de canadese overheid niet heeft moeten toekijken hoe Pfizer met zijn inhaler, die voor de gezondheid slechter is, wel aan de bak kwam en Generex niet. Er zal m.i. nu toch druk uitgeoefend worden, al moeten we natuurlijk wel geduld blijven houden. Vergeet niet dat, voordat er goedkeuring is, het aandeel nog diverse malen zal worden geshuffeld.
    Een behoorlijke shuffel omhoog kunnen we krijgen als de eerste keer het woord "Vogelgriep" in Amerika valt. Dat lijkt mij een mooi moment om nog een keer uit te stappen.

    Henks
  9. [verwijderd] 5 maart 2006 17:06
    quote:

    Henk Snaph schreef:

    [quote=ronald76]
    [quote=mcrel]
    v/d [quote=ronald76]
    According to the IDF Diabetes Atlas 2nd edition, in 2003 the five countries with the largest numbers of persons with diabetes were India (35.5 million), China (23.8 million), the United States (16 million), Russia (9.7 million) and Japan (6.7 million).

    Ik snap niet dat ze nog zoveel moeite doen om de U.S in te komen.

    Skip the U.S and go elsewhere.
    Als die kuttekoppen daar niet in het gareel willen vallen ze maar dood.

    Ga naar China en India daar ligt genoeg potentie.

    GRoet,Ronald.

    [/quote]
    Waar denk je dat ze meeste winst per patient kunnen maken?

    Juist in de U.S. en eenmaal FDA-goedkeuring,dan volgt de rest vanzelf.
    Zoals normaal in 99 v/d 100 beleggingen moet je gewoon geduld hebben.

    Mcrel
    [/quote]

    WInst per patient is belangrijk,in een vroeg stadium als dit is ok het aantal patienten belangrijk.
    Des te meer mensen het medicijn gebruiken en er baat bij hebben,des te makkelijker het word toestemming te krijgen van bv. die yanken.

    Groet, Ronald.
    [/quote]

    Mijn visie is dat na de ontmoeting met de canadese overheid het projekt sneller zal verlopen dan tot nu toe.
    Deze uitnodiging is niet voor niets aan Generex gedaan. Wie zegt dat de canadese overheid niet heeft moeten toekijken hoe Pfizer met zijn inhaler, die voor de gezondheid slechter is, wel aan de bak kwam en Generex niet. Er zal m.i. nu toch druk uitgeoefend worden, al moeten we natuurlijk wel geduld blijven houden. Vergeet niet dat, voordat er goedkeuring is, het aandeel nog diverse malen zal worden geshuffeld.
    Een behoorlijke shuffel omhoog kunnen we krijgen als de eerste keer het woord "Vogelgriep" in Amerika valt. Dat lijkt mij een mooi moment om nog een keer uit te stappen.

    Henks
    According to the MOH, the overall market in China for diabetes therapies is estimated to be approximately $2.2 billion and is growing at approximately 20% per year in urban areas.
  10. [verwijderd] 5 maart 2006 22:07
    www.smartmoney.com/aheadofthecurve/in...

    Here are the companies in my avian flu index (disclosure — I own long positions in every one):
    Alnylam Pharma (ALNY), Alpha Pro Tech (APT), Avant Immunothp (AVAN), Avi Biopharm (AVII), Biocryst Pharma (BCRX), Cal-Maine Foods (CALM), Carrington Labs (CARN), Chiron (CHIR), Crucell-Adr (CRXL), Embrex (EMBX), Gilead Sciences (GILD), Generex Biotech (GNBT), Hemispherx Bio (HEB), Medimmune (MEDI), Nastech Pharma (NSTK), Novavax (NVAX), Premium Std (PORK), Quidel (QDEL), Sonovac Biotech (SVA), Vical (VICL), VaxGen (VXGN).

    Was getekend.....Donald Luskin
  11. Henk Snaph 5 maart 2006 22:10
    quote:

    DieGroeneGigant schreef:

    www.smartmoney.com/aheadofthecurve/in...

    Here are the companies in my avian flu index (disclosure — I own long positions in every one):
    Alnylam Pharma (ALNY), Alpha Pro Tech (APT), Avant Immunothp (AVAN), Avi Biopharm (AVII), Biocryst Pharma (BCRX), Cal-Maine Foods (CALM), Carrington Labs (CARN), Chiron (CHIR), Crucell-Adr (CRXL), Embrex (EMBX), Gilead Sciences (GILD), Generex Biotech (GNBT), Hemispherx Bio (HEB), Medimmune (MEDI), Nastech Pharma (NSTK), Novavax (NVAX), Premium Std (PORK), Quidel (QDEL), Sonovac Biotech (SVA), Vical (VICL), VaxGen (VXGN).

    Was getekend.....Donald Luskin
    Gigant, heel leuk maar je kunt toch niet in alles long gaan.En een keuze uit deze lijst maken lijkt me ondoenlijk.

    Henks
  12. [verwijderd] 6 maart 2006 09:38
    Dat ligt geheel aan de grootte van je vermogen en hoeveel risico je wilt lopen.. Alles in GNBT is natuurlijk een risico. Spreiden in gelijksoortige aandelen is dan een veilig alternatief.

    Je zou ook tussen de fondsen kunnen hoppen. Als gnbt flink is gestegen dan kan die iets afbouwen om in achterblijver Qdel te investeren.

    't zijn maar wat gedachten...
  13. [verwijderd] 7 maart 2006 11:57
    $2,20 lijkt een mooie bodum te zijn.We zullen moeten wachten op het volgende goede nieuws of tot iedereen zijn Finisar-winst opnieuw gaat beleggen.
    LOL.

    Mcrel
  14. [verwijderd] 7 maart 2006 12:01
    quote:

    mcrel schreef:

    $2,20 lijkt een mooie bodum te zijn.We zullen moeten wachten op het volgende goede nieuws of tot iedereen zijn Finisar-winst opnieuw gaat beleggen.
    LOL.

    Mcrel
    heheh

    :p
  15. Nel 7 maart 2006 13:22
    verwacht komende mnd nog wel nieuws omtrend dit bericht.

    QUITO, Ecuador, Nov 28 (Reuters) - Canada's Generex Biotechnology Corp. (GNBT.O: Quote, Profile, Research) and Ecuador's PharmaBrand S.A. said on Monday they would start selling an oral insulin spray for diabetics in Latin America next year.
    The spray would be first sold in Ecuador and then in other countries in the region. The companies said at a press conference that the product, to be sold under the name Oral-lyn, could have annual sales of about $300 million.

    "The great advantage of this product is that it is administered in a more natural way," said Camilo Felix, chief doctor for PharmaBrand.

    The companies have a joint venture that includes the manufacture, marketing, distribution and sale of the Generex drug in Latam.

    They said they would begin selling the spray in the rest of Latin America in the second half of 2006.

    The insulin is administered orally via a spray that is similar to an asthma inhaler. The company said the spray would lower the amount of daily shots needed by people with type 1 diabetes, usually children and young adults.

    Diabetes, which affects six percent of the world's population or about 360 million people, prevents the body from properly using the hormone insulin to control blood sugar.

    staat niet in dit bericht vermeld maar men zou het eerste kwartaal beginnen met de verkoop.

    succes
  16. Henk Snaph 7 maart 2006 13:30
    quote:

    papaa schreef:

    verwacht komende mnd nog wel nieuws omtrend dit bericht.

    QUITO, Ecuador, Nov 28 (Reuters) - Canada's Generex Biotechnology Corp. (GNBT.O: Quote, Profile, Research) and Ecuador's PharmaBrand S.A. said on Monday they would start selling an oral insulin spray for diabetics in Latin America next year.
    The spray would be first sold in Ecuador and then in other countries in the region. The companies said at a press conference that the product, to be sold under the name Oral-lyn, could have annual sales of about $300 million.

    "The great advantage of this product is that it is administered in a more natural way," said Camilo Felix, chief doctor for PharmaBrand.

    The companies have a joint venture that includes the manufacture, marketing, distribution and sale of the Generex drug in Latam.

    They said they would begin selling the spray in the rest of Latin America in the second half of 2006.

    The insulin is administered orally via a spray that is similar to an asthma inhaler. The company said the spray would lower the amount of daily shots needed by people with type 1 diabetes, usually children and young adults.

    Diabetes, which affects six percent of the world's population or about 360 million people, prevents the body from properly using the hormone insulin to control blood sugar.

    staat niet in dit bericht vermeld maar men zou het eerste kwartaal beginnen met de verkoop.

    succes
    papaa, er heeft al een bericht gestaan dat men half januari begonnen is met de verkoop van Oral-lyn in Equador en van daaruit de rest van Z-Amerika wil gaan doen.

    Henks
  17. Henk Snaph 7 maart 2006 13:39
    quote:

    papaa schreef:

    zou je dit bericht kunnen plaatsen,

    bvd
    papaa, ik zal dat op moeten zoeken, maar in dat zelfde bericht stond toen dat er 700.000 patronen voor Oral-lyn besteld hadden in Frankrijk voor de verkoop in Equador.

    Henks
2.656 Posts
Pagina: «« 1 ... 88 89 90 91 92 ... 133 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.131
AB InBev 2 5.541
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.270
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.903
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.867
Aedifica 3 927
Aegon 3.258 323.113
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.907
Agfa-Gevaert 14 2.066
Ahold 3.538 74.353
Air France - KLM 1.025 35.301
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.054
Alfen 16 25.347
Allfunds Group 4 1.520
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.089
AMG 972 134.529
AMS 3 73
Amsterdam Commodities 305 6.747
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 497
Antonov 22.632 153.605
Aperam 92 15.072
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.035 321.018
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.360
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.647
ASML 1.766 110.777
ASR Nederland 21 4.515
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.184
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449